Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
iwAL 2022
16–18 September 2022 | Nice, France
VJHemOnc is pleased to be the official media partner for the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 17 – 18 September, 2022.
The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in acute leukemias with the aim to optimize clinical care.
Session 1: Current challenges in clinical genomics
CHIP and clonal hematopoiesis in relation to AML
Koichi Takahashi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Fitness of leukemic stem cells
Claudia Lengerke University Hospital Tübingen , Tübingen, Germany
Current challenges in clinical genomics
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Genomics and their clinical application for secondary AML
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Session 2: What is the standard of care in AML in 2022?
Improving intensive chemotherapy approaches in frontline AML
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Maintenance therapy for whom?
Andrew Wei Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Institute of Medical Research, University of Melbourne, Melbourne, Australia
Which patients should have allogeneic transplants in 2022?
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Optimal transplant conditioning regimen in AML
Alessandro Rambaldi University of Milan, Milan, Italy
Optimizing therapy in secondary AML/RWE of CPX‐351
Christina Rautenberg University Hospital Essen, Essen, Germany
Targeted approaches for IDH‐mutated AML ‐ venetoclax or IDHi?
Stéphane de Botton Gustave Roussy, Paris, France
Current approach for relapsed FLT3‐mutant AML
Jessica Altman Northwestern University, Chicago, IL, United States
Session 3: Novel treatment strategies in ALL
Innovation in the treatment of ALL
Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States
Ponatinib combination strategies
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Progress in treatment of AYA ALL
Nicolas Boissel Saint-Louis Hospital, Paris, France
Open questions in Ph+ ALL
Robin Foà Sapienza University of Rome, Italy
Updates in asparaginase treatment strategies
Rob Pieters Princess Máxima Center, Utrecht, Netherlands
Session 4: New frontiers in MRD
Part 1 – ALL clinical practice
MRD in adult Ph‐/BCR‐ABL‐negative ALL: how best to eradicate?
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Session 4: New frontiers in MRD
Part 2 – AML clinical practice
Single‐cell sequencing and clinical applicability in detection and therapy of AML
Catherine Smith University of California, San Francisco, San Francisco, CA, United States
Value of MRD assessment in non‐intensive regimens in AML
Farhad Ravandi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Novel approaches for integrating MRD into clinical trials
Andrew Wei Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Institute of Medical Research, University of Melbourne, Melbourne, Australia
Session 5: Special session on regulatory endpoints in AML
The FDA’s perspective on regulatory endpoints in AML
Kelly Norsworthy Johns Hopkins Medicine, Baltimore, MD, United States
A clinician’s perspective on endpoints and drug development in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 6: BPDCN & CMML
Updates in diagnosis, pathogenesis and future directions in BPDCN
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Updates in CMML diagnosis and treatment, future targets
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Session 7: ELN 2022 classifications
ELN 2022 classifications
Andrew Wei Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Institute of Medical Research, University of Melbourne, Melbourne, Australia
Session 8: Novel targets, combinations and treatments in AML
Part 1 – What is the next AML blockbuster?
Challenges in the treatment of high‐risk AML
Richard Stone Dana-Farber Cancer Institute, Boston, MA, United States
Doublet and triplet combinations in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Emerging novel antibody‐drug conjugates
Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States
TP53 treatment strategies in AML
Thomas Cluzeau Central University Hospital of Nice, France
Menin inhibitors in AML
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Anti‐CD47
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Session 8: Novel targets, combinations and treatments in AML
Part 2 – What do we know about drug resistance?
Understanding and overcoming resistance to IDHi
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Targeting resistance to venetoclax‐based therapies
Marina Konopleva Albert Einstein College of Medicine, New York City, NY, United States
Resistance to FLT3 inhibitors
Alexander Perl University of Pennsylvania, Philadelphia, PA, United States
Epigenetic therapies and Epitranscriptomics
Carsten Müller‐Tidow Heidelberg University Hospital, Heidelberg, Germany
Session 9: T‐cell engagement
Part 1 – roadmap on how to treat relapsed ALL
Use of monoclonal antibodies in the CAR T‐cell era
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Integration of immunotherapies into frontline ALL management
Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 9: T‐cell engagement
Part 2 – CAR-T in ALL
Predicting response to CAR‐T
Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Tisagenlecleucel in B‐ALL
Sara Ghorashian Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
ZUMA‐3 and brexucabtagene autoleucel indication for adult ALL
Nicolas Boissel Saint-Louis Hospital, Paris, France
Session 10: Immunotherapeutics in AML
Pitfalls and future strategies for immunotherapies in AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
CLL1‐CD33 cCAR‐T
Fang Liu Chengdu Military General Hospital, Sichuan, China
Novel targets for CAR‐T in AML
Michael Hudecek University of Würzburg, Würzburg, Germany
Immune checkpoint inhibitors in AML
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Emerging NK cell‐based therapies in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Which CAR T‐cell strategy in AML has the most promise?
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
iwAL 2022 was supported by:
For the latest updates in AML & ALL, click below to explore our dedicated channels
